Zyngenia, Inc Email Format

Biotechnology ResearchMaryland, United States11-50 Employees

Zyngenia is developing a new class of biotherapeutics that better address the complexity of diseases by the simultaneous targeting of multiple physiologic pathways. These highly specific, single molecule drugs are able to more effectively treat multifactorial diseases such as cancer, inflammation and autoimmune disorders. The Company's pipeline is comprised of monoclonal antibody (mAb)-based drugs that are able to concomitantly engage several validated disease targets through the genetic fusion of additional peptide binding motifs to the mAb. Zyngenia has advanced three programs into preclinical development and achieved preclinical proof-of-concept with both bi-specific and tri-specific programs in cancer and inflammation. The Company's game-changing technology surpasses other biological platforms in creating innovative and differentiated monoclonal antibody-based therapeutics (called Zybodies™) that combine multi-functionality with the drug-like properties of conventional monoclonal antibodies, all while using standard commercial production processes. This technology platform and the resulting programs generate multiple opportunities for discovery and licensing partnerships to address a broad spectrum of diseases.

Sign up for free to view info

Company overview Employee directory